



PRODUCT: **NEXLETOL**

COMPANY: Esperion Therapeutics Inc.

THERAPEUTIC AREA & INDICATION:
Treatment of hypercholesterolemia

ABOUT THE PRODUCT

NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. In spite of advances in lipid management, hyperlipidemia remains a dire epidemic worldwide. It's why ESPERION Therapeutics, Inc., the Lipid Management Company, developed oral, once-daily NEXLETOL® (bempedoic acid). Its active ingredient is bempedoic acid, the first adenosine triphosphate citrate lyase (ACL) inhibitor, which lowers LDL-C by working 2 steps upstream from statins in the cholesterol biosynthesis pathway in the liver. When added to maximally tolerated statin therapy, NEXLETOL delivered significant mean LDL-C reduction of up to 18% vs placebo, with incidence of most common adverse reactions generally comparable to placebo. See NEXLETOLHCP.com for product information, including side effects.